PAVmed Inc (PAVM) - Net Assets
Based on the latest financial reports, PAVmed Inc (PAVM) has net assets worth $25.79 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($38.07 Million) and total liabilities ($12.28 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are PAVmed Inc's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $25.79 Million |
| % of Total Assets | 67.74% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -1209.45% |
| Growth Volatility | 111.3 |
PAVmed Inc - Net Assets Trend (2014–2024)
This chart illustrates how PAVmed Inc's net assets have evolved over time, based on quarterly financial data. Also explore PAVmed Inc balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for PAVmed Inc (2014–2024)
The table below shows the annual net assets of PAVmed Inc from 2014 to 2024. For live valuation and market cap data, see PAVmed Inc (PAVM) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-7.03 Million | +70.72% |
| 2023-12-31 | $-24.02 Million | -319.66% |
| 2022-12-31 | $10.93 Million | -86.23% |
| 2021-12-31 | $79.42 Million | +16890.27% |
| 2020-12-31 | $-473.00K | +89.80% |
| 2019-12-31 | $-4.64 Million | -87.31% |
| 2018-12-31 | $-2.48 Million | +13.07% |
| 2017-12-31 | $-2.85 Million | -792.71% |
| 2016-12-31 | $-319.07K | -150.33% |
| 2015-12-31 | $633.92K | -20.24% |
| 2014-12-31 | $794.83K | -- |
Equity Component Analysis
This analysis shows how different components contribute to PAVmed Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 25469061600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $11.00K | % |
| Other Components | $252.46 Million | % |
| Total Equity | $-2.50 Million | 100.00% |
PAVmed Inc Competitors by Market Cap
The table below lists competitors of PAVmed Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kolon Global Corp
KO:003075
|
$7.86 Million |
|
Pure Energy Minerals Ltd
V:PE
|
$7.86 Million |
|
T.Krungthai Industries Public Company Limited
BK:TKT
|
$7.87 Million |
|
BRITANNIA LIFE SCIENCES
F:L020
|
$7.87 Million |
|
Emerson Radio Corporation
NYSE MKT:MSN
|
$7.86 Million |
|
ClearOne Inc
NASDAQ:CLRO
|
$7.86 Million |
|
Moonpig Group PLC
LSE:MOON
|
$7.85 Million |
|
LCK Global Kedaton
JK:LCKM
|
$7.85 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PAVmed Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -53,831,000 to -2,495,000, a change of 51,336,000.
- Net income of 39,791,000 contributed positively to equity growth.
- Share repurchases of 62,000,000 reduced equity.
- New share issuances of 31,749,000 increased equity.
- Other comprehensive income increased equity by 2,993,000,000.
- Other factors decreased equity by 2,951,204,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $39.79 Million | +1594.83% |
| Share Repurchases | $62.00 Million | -2484.97% |
| Share Issuances | $31.75 Million | +1272.51% |
| Other Comprehensive Income | $2.99 Billion | +119959.92% |
| Other Changes | $-2.95 Billion | -118284.73% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares PAVmed Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $26.59 | $8.53 | x |
| 2015-12-31 | $21.43 | $8.53 | x |
| 2016-12-31 | $-11.07 | $8.53 | x |
| 2017-12-31 | $-0.21 | $8.53 | x |
| 2018-12-31 | $-46.76 | $8.53 | x |
| 2019-12-31 | $-56.98 | $8.53 | x |
| 2020-12-31 | $17.99 | $8.53 | x |
| 2021-12-31 | $357.99 | $8.53 | x |
| 2022-12-31 | $-48.91 | $8.53 | x |
| 2023-12-31 | $-223.32 | $8.53 | x |
| 2024-12-31 | $-1.15 | $8.53 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PAVmed Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1328.58%
- • Asset Turnover: 0.10x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-203.52%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -69.04% | 0.00% | 0.00x | 1.06x | $-628.25K |
| 2015 | -280.26% | 0.00% | 0.00x | 1.92x | $-1.84 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.62 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.23 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.74 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-15.55 Million |
| 2020 | -1807.81% | 0.00% | 0.00x | 10.43x | $-34.47 Million |
| 2021 | -81.64% | -10069.40% | 0.01x | 1.41x | $-56.51 Million |
| 2022 | 0.00% | -23602.92% | 0.01x | 0.00x | $-88.01 Million |
| 2023 | 0.00% | -2617.25% | 0.07x | 0.00x | $-58.79 Million |
| 2024 | 0.00% | 1328.58% | 0.10x | 0.00x | $40.04 Million |
Industry Comparison
This section compares PAVmed Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,432,799,891
- Average return on equity (ROE) among peers: -74.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PAVmed Inc (PAVM) | $25.79 Million | -69.04% | 0.48x | $7.86 Million |
| Abbott Laboratories (ABT) | $24.16 Billion | 9.46% | 0.81x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $16.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.60 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $89.39 Million | 8.74% | 0.25x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $125.55 Million |
About PAVmed Inc
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing… Read more